VGX Pharma gets $23M NIH grant for HIV vax

Start-up VGX Pharmaceuticals has been awarded $23 million from the National Institutes of Health to complete the development and manufacturing of their preventive HIV vaccine, which is now in the precinical stage. The vaccine, Pennvax-G, was developed by VGX co-founder Dr. David B. Weiner of the University of Pennsylvania.

"This contract substantiates the NIH's endorsement of VGX's approach to DNA vaccines and their delivery via our proprietary in vivo electroporation technology," said Dr. J. Joseph Kim, Co-founder, President and CEO of VGX. "HIV remains a challenging and tremendously important area of medical research, and we value the NIH's support to further evaluate the immunogenicity and efficacy of our electroporation delivery system and novel preventive HIV vaccine candidate."

Despite the rocky markets, as of October 1, 2008, the privately-owned company hopes to complete its IPO before the end of the year.

- check out the VGX release

Suggested Articles

GSK's Shingrix has generated blockbuster sales early in the launch, but there's a lot of remaining opportunity, an exec said at JPM.

Quickly after Merck's world-first Ebola vaccine approval in Europe, U.S. authorities licensed the shot.

In an effort to stop an Ebola outbreak that has claimed 2,200 lives at the Rwanda border, J&J is shipping 200,000 doses of its vaccine to the country.